title: Enzyme replacement therapy started at birth improves outcome in difficult-to-treat organs in mucopolysaccharidosis I mice.
abstract: Since we previously observed that in patients with mucopolysaccharidosis (MPS) the storage of undegraded glycosaminoglycans (GAG) occurs from birth, in the present study we aimed to compare normal, untreated MPS I mice (knockout for alpha-l-iduronidase-IDUA), and MPS I mice treated with enzyme replacement therapy (ERT, Laronidase, 1.2mg/kg every 2 weeks) started from birth (ERT-neo) or from 2 months of age (ERT-ad). All mice were sacrificed at 6 months. Both treatments were equally effective in normalizing GAG levels in the viscera but had no detectable effect on the joint. Heart function was also improved with both treatments. On the other hand, mice treated from birth presented better outcomes in the difficult-to-treat aortas and heart valves. Surprisingly, both groups had improvements in behavior tests, and normalization of GAG levels in the brain and IDUA injection resulted in detectable levels of enzyme in the brain tissue 1h after administration. ERT-ad mice developed significantly more anti-IDUA-IgG antibodies, and mice that didn't develop antibodies had better performances in behavior tests, indicating that development of antibodies may reduce enzyme bioavailability. Our results suggest that ERT started from birth leads to better outcomes in the aorta and heart valves, as well as a reduction in antibody levels. Some poor vascularized organs, such as the joints, had partial or no benefit and ancillary therapies might be needed for patients. The results presented here support the idea that ERT started from birth leads to better treatment outcomes and should be considered whenever possible, a observation that gains relevance as newborn screening programs are being considered for MPS and other treatable lysosomal storage disorders.
authors.affiliation: Centro de Terapia Gênica, Hospital de Clinicas de Porto Alegre, RS, Brazil.
authors.forename: Guilherme
authors.initials: G
authors.lastname: Baldo
authors.forename: Fabiana Q
authors.initials: FQ
authors.lastname: Mayer
authors.forename: Bárbara Z
authors.initials: BZ
authors.lastname: Martinelli
authors.forename: Talita G
authors.initials: TG
authors.lastname: de Carvalho
authors.forename: Fabiola S
authors.initials: FS
authors.lastname: Meyer
authors.forename: Patrícia G
authors.initials: PG
authors.lastname: de Oliveira
authors.forename: Luise
authors.initials: L
authors.lastname: Meurer
authors.forename: Angela
authors.initials: A
authors.lastname: Tavares
authors.forename: Ursula
authors.initials: U
authors.lastname: Matte
authors.forename: Roberto
authors.initials: R
authors.lastname: Giugliani
mesh_terms: D000818:Animals; D001921:Brain / Q000201:enzymology / Q000473:pathology; D004195:Disease Models, Animal; D056947:Enzyme Replacement Therapy; D005260:Female; D005822:Genetic Vectors; D006025:Glycosaminoglycans / Q000235:genetics / Q000378:metabolism*; D006801:Humans; D007068:Iduronidase / Q000008:administration & dosage / Q000235:genetics* / Q000378:metabolism; D008247:Lysosomes / Q000201:enzymology / Q000473:pathology; D051379:Mice; D018345:Mice, Knockout; D008059:Mucopolysaccharidosis I / Q000201:enzymology / Q000235:genetics / Q000628:therapy*
chemical_list: D006025:Glycosaminoglycans; D007068:Iduronidase